With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.141774-61-0,tert-Butyl (piperidin-2-ylmethyl)carbamate,as a common compound, the synthetic route is as follows.
To a solution of Compound L (14.71 g, 46.7 mmol) in THF(250 mE) at -60 C. was added 0.5 M KHMDS solution inTHF (103 mE) dropwise. After stirring at -60 C. for 30 mithe reaction mixture was added to a solution of 4-nitrophenylchloroformate at -60 C. (9.41 g, 46.7 mmol) in THF (200This reaction mixture was then stirred for 30 mm at -60C., followed by addition of piperidine-2-yl-methylcarbamicacid tert-butyl ester, also referred to herein as (R,S)-piperi-dine-2-yl-methylcarbamic acid tert-butyl ester, (5.0 g, 23.3mmol) in portions. The reaction was allowed to warm toambient temperature and then stirred for 18 h. The reactionwas then concentrated under vacuum, and the residue dilutedwith EtOAc (500 mE). The mixture was then washed withwater (2×250 mE) and brine (250 mE). The organic layer wasseparated, dried over Na2504, and filtered. Removal of sol-vents under vacuum afforded crude Compound N. CrudeCompound N was purified by flash chromatography using100% EtOAc. Removal of solvent under vacuum affordedCompound N in 50% yield (6.5 g, 11.7 mmol) as a whitesolid. EC-MS [M+H] 556.1 (C30H41N307+H, calc: 555.3)., 141774-61-0
The synthetic route of 141774-61-0 has been constantly updated, and we look forward to future research findings.
Reference：
Patent; Signature Therapeutics, Inc.; Jenkins, Thomas E.; Husfeld, Craig O.; US9139612; (2015); B2;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem